PCSK9 inhibitors and treatment targets: an audit-based evaluation of a specialist lipid clinic


  • Anirudh Suresh Chelsea and Westminster Hospital NHS Foundation Trust
  • Aikaterini Theodoraki Chelsea and Westminster Hospital NHS Foundation Trust
  • Emily Ward Chelsea and Westminster Hospital NHS Foundation Trust
  • Michael Feher Chelsea & Westminster Hospital




PCSK9 inhibitors, low-density lipoprotein, cholesterol, cardiovascular disease, familial hypercholesterolaemia, guideline targets


Background: Trial evidence for lower LDL cholesterol (LDL-C) treatment targets for cardiovascular benefit were incorporated into recent European Society of Cardiology/European Atherosclerosis Society and NICE guidelines. Treatment targets are LDL-C <1.4mmol/L, LDL-C <1.8mmol/L and ≥50% LDL-C reduction for atherosclerotic cardiovascular disease (ASCVD) and/or Familial Hypercholesterolaemia (FH). There is limited real-world evidence of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is), with enhanced LDL-C lowering, achieving these targets.

Aims: To assess attainment of guideline LDL-C targets using PCSK9is ± oral lipid-lowering therapies (LLT) in ASCVD and/or FH.

Methods: Clinic-based audit using retrospective case-note review of adults prescribed PCSK9is. Anonymised data were collected before and after PCSK9i initiation. Standards were attainment of LDL-C <1.8mmol/L, LDL-C <1.4mmol/L and ≥50% LDL-C reduction.

Results: Fifty-five patients (mean age 60.8 years) receiving PCSK9is (35% monotherapy; median treatment duration 1.5 years) were identified (ASCVD, n=50; FH, n=18). Target attainment was 80% for ≥50% LDL-C reduction, 46% for LDL-C <1.8mmol/L and 24% for LDL-C <1.4mmol/L. Greater attainment of these targets occurred with ≥2 additional LLTs versus one additional LLT or PCSK9i monotherapy.

Conclusion: Most ASCVD and/or FH patients achieved ≥50% LDL-C reductions with PCSK9is. Fewer achieved LDL-C <1.8mmol/L and <1.4mmol/L targets. PCSK9is in combination with other LLT achieved targets more often compared to PCSK9i monotherapy. Achievement of recommended lipid targets may require greater use of PCSK9i combination therapies.


Mach F, Baigent C, Catapano AL et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J 2020;41(1):111-88.

NHS Accelerated Access Collaborative. Summary of national guidance for lipid management. https://www.england.nhs.uk/aac/publication/summary-of-national-guidance-for-lipid-management/ [Accessed 11 May 2021].

Schwartz GG, Steg PG, Szarek M et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018;379(22):2097-107. https://doi.org/10.1056/NEJMoa1801174

Sabatine MS, Giugliano RP, Keech AC et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376(18):1713-22. https://doi.org/10.1056/NEJMoa1615664

Nicholls SJ, Puri R, Anderson T et al. Effect of evolocumab on progression of

coronary disease in statin-treated patients: The GLAGOV randomized clinical trial. JAMA 2016;316(22):2373-84.

Robinson JG, Farnier M, Krempf M et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372(16):1489-99. https://doi.org/10.1056/NEJMoa1501031

Kastelein JJP, Ginsberg HN, Langslet G et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J 2015;36(43):2996-3003. https://doi.org/10.1093/eurheartj/ehv370

aal FJ, Stein EA, Dufour R et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 2015;385(9965):331-40. https://doi.org/10.1016/S0140-6736(14)61399-4

Ginsberg HN, Rader DJ, Raal FJ et al. Efficacy and safety of alirocumab in patients with heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher. Cardiovasc Drugs Ther 2016;30(5):473-83. https://doi.org/10.1007/s10557-016-6685-y

Ray KK, Molemans B, Schoonen WM et al. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol 2021;28(11):1279-89.

Zafrir B, Egbaria A, Stein N, Elis A, Saliba W. PCSK9 inhibition in clinical practice: Treatment patterns and attainment of lipid goals in a large health maintenance organization. J Clin Lipidol 2021;15(1):202-11.e2. https://doi.org/10.1016/j.jacl.2020.11.004

Fischer LT, Hochfellner DA, Knoll L et al. Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus. Cardiovasc Diabetol 2021;20(1):89. https://doi.org/10.1186/s12933-021-01283-w

Ference BA, Ginsberg HN, Graham I et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017;38(32):2459-72. https://doi.org/10.1093/eurheartj/ehx144






Original Research